Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

Published:2021-04-24 Issue:2 Volume:8 Page:863-876
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Li SiNi,Li JianHe,Peng LiuBao,Li YaMin,Wan XiaoMin

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-021-00308-w.pdf

Reference42 articles.

1. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–22. https://doi.org/10.1136/annrheumdis-2013-204627.

2. Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, et al. Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):251. https://doi.org/10.1186/s13075-017-1457-z.

3. Li ZG. A new look at rheumatology in China–opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):313–7. https://doi.org/10.1038/nrrheum.2014.218.

4. Zhang X, Mu R, Wang X, Xu C, Duan T, An Y, et al. The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. Rheumatology. 2015;54(8):1478–87. https://doi.org/10.1093/rheumatology/kev014.

5. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. https://doi.org/10.1002/acr.22783.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China;Journal of Medical Economics;2024-09-13

2. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

3. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies;Expert Review of Pharmacoeconomics & Outcomes Research;2023-08-28

4. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies;Frontiers in Pharmacology;2022-12-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3